Lilly's gastric cancer drug meets late-stage goal
Oct 15 (Reuters) - Eli Lilly and Co said a late-stage study of its experimental gastric cancer drug met its main goal of improving overall survival.
The study, compared the drug ramucirumab to a placebo and the drug was tested as a second-line treatment in patients with cancers that originate in the stomach.
The study, named REGARD, also improved survival without the cancer worsening.
- South Korea expands air defense zone to partially overlap China's |
- Dynasty's Congress party punished in Indian state elections
- U.S. war veteran released by North Korea returns home |
- Thai PM proposes referendum on her future as protesters prepare big push
- Ukraine opposition rally keeps pressure on Yanukovich